Early detection of acute coronary syndromes and risk stratification by multimarker analysis
1University of California, Department of Laboratory Medicine, San Francisco, CA, USA. wualan@labmed2.ucsf.edu
Insights
New biomarkers are needed for early acute myocardial infarction (AMI) diagnosis, as troponin levels can be normal initially. Multimarker testing approaches, utilizing proteomics or pathophysiology, show promise for improved early detection and risk stratification.
Area of Science:
- Biochemistry
- Cardiology
- Bioinformatics
Background:
- Cardiac troponin is the standard biomarker for acute myocardial infarction (AMI) diagnosis and short-term risk stratification.
- Current troponin tests may be normal in early AMI presentation, necessitating research into novel early diagnostic markers.
- Despite extensive research, no single new biomarker has demonstrated sufficient clinical sensitivity and specificity for early AMI detection.
Purpose of the Study:
- To explore novel approaches for discovering early diagnostic markers for acute myocardial infarction (AMI).
- To investigate the potential of multimarker testing strategies for improved AMI diagnosis and risk stratification.
- To review current methodologies for identifying and combining multiple biomarkers for cardiac events.
Main Methods:
- Reviewing proteomic approaches to identify differences in biochemical signatures between healthy and diseased individuals.
- Examining pathophysiologic approaches that combine biomarkers related to known disease pathways.
- Discussing the necessity of bioinformatic algorithms, such as Multimarker Index, classification and regression trees, and neural networks, for integrating multimarker data.
Main Results:
- No single biomarker has met the required clinical sensitivity and specificity for early AMI detection.
- Multimarker testing is advocated as a strategy to overcome the limitations of single-biomarker approaches.
- Proteomic and pathophysiologic strategies, combined with bioinformatic analysis, are key to discovering and utilizing novel multimarker panels.
Conclusions:
- The development of early diagnostic markers for AMI remains a critical unmet need.
- Multimarker testing represents a promising strategy for enhancing the early diagnosis and risk stratification of AMI.
- Advanced bioinformatic algorithms are essential for effectively integrating data from multiple biomarkers to improve clinical decision-making in cardiology.
Abstract:
Cardiac troponin is the standard biomarker for the diagnosis of acute myocardial infarction (AMI) and risk stratification for short-term adverse cardiac events (death, AMI or need for revascularization). Unfortunately, the concentration of troponin in blood is normal in AMI patients who present early after the onset of symptoms. As such, there is active research being conducted in finding early markers of AMI and risk stratification. Despite years of testing dozens of candidates, no single test has had the necessary clinical sensitivity and specificity for this indication. Therefore, many researchers have advocated multimarker testing. There are two approaches that have been taken for discovering new markers. The proteomic approach involves focusing on the differences in the biochemical signatures between the tissues or biological fluids of normal compared with diseased individuals. Specific biochemical targets are not preselected. The pathophysiologic approach involves combining biomarkers that indicate a particular pathway or event known to be involved in the disease process. In both approaches, some bioinformatic algorithm will be necessary in order to combine the information provided by the individual tests. Representative approaches include the Multimarker Index, classification and regression tree analysis and neural networks.
Related Concept Videos
01:30Acute Coronary Syndrome III: Diagnostic Studies
01:30Acute Coronary Syndrome I: Introduction
01:19Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
01:25Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT
01:20Blood Studies for Cardiovascular System I: Cardiac Biomarkers
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
01:30Coronary Artery Disease I: Introduction